Jubilant will provide drug discovery services across early discovery, synthetic and medicinal chemistry, including scale up and preclinical services. The research for the project will primarily take place at Jubilant Biosys R&D labs in India, as well as its Discovery Center in the U.S. Jubilant will receive research funding, pre-defined research milestones, as well as royalties on sales. Orion will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights.
Dr. Subir Kumar Basak, president of Jubilant Biosys, said, “We are excited to partner with Orion to offer integrated drug discovery services. Over the past few years, we have been strengthening our therapeutic area focused discovery platform, and this partnership serves as a validation of our efforts. We are confident of offering successful results to Orion at various stages of research.”
Dr. Jukka Sallinen, head of CNS Research of Orion Pharma R&D, said, “Jubilant Biosys is widely recognized for its expertise in offering integrated services in Drug Discovery and Development Solutions and for its prodigious capabilities in Pain and Inflammation. With established ability to develop successful drugs, we consider Jubilant as our ideal partner to take forward our strategic business plans with optimum time-to-market and accuracy.”